U.S. market Closed. Opens in 7 hours 59 minutes

CATX | Perspective Therapeutics, Inc. Stock Overview

(Stock Exchange: NYSE)
Day's Range 2.0100 - 2.2000
52 Week Range 2.0100 - 19.10
Beta 1.38
Implied Volatility 394.50%
IV Rank 75.98%
Day's Volume 949,978
Average Volume 768,252
Shares Outstanding 74,051,800
Market Cap 157,730,334
Sector Healthcare
Industry Medical - Devices
IPO Date 2005-11-10
Valuation
Profitability
Growth
Health
P/E Ratio -1.75
Forward P/E Ratio N/A
EPS -1.22
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 116
Country USA
Website CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX's peers: KIDS, OFIX, SGHT, NPCE, CVRX, PAVM, OSA, HYPR, ELMD, SRDX, FNA, LIVN, LUNG, SIBN
*Chart delayed
Analyzing fundamentals for CATX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see CATX Fundamentals page.

Watching at CATX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CATX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙